

## Diabetic Retinopathy Guideline Committee Meeting 7

**Date:** 2<sup>nd</sup> December 2022  
**Location:** Virtual Meeting via Zoom  
**Minutes:** Final

<b>Committee members present:</b>	
Mike Burdon (Chair)	Present for all items
John Anderson	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Christiana Dinah	Present for all items
Noemi Lois	Present for all items
Louis Savage	Present for all items
Diva Shah	Present for all items
Bernadette Warren	Present for items 5-8
Becky Wei Luo	Present for all items

<b>In attendance:</b>		
Keona Bennett	Administrator, Guideline Development Team	Present for item 1
Catrina Charlton	Guideline Commissioning Manager, NICE	Present for all items
Jon Littler	Project Manager, Guideline Development Team	Present for all items
Clare Dadswell	Senior Technical Analyst, Guideline Development Team	Present for all items
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Ahmed Yousef	Technical Analyst, Guideline Development Team	Present for all items

<b>Apologies:</b>	
Yvonne Coalbran	Committee Member
Astrid Aregui	Senior Medical Editor, NICE
Magdalena Watras	Medicines Lead, NICE
Becky Wei Luo	Committee Member
Philip Williams	Resource Impact Lead, NICE

## **1. Welcome and DOIs for the meeting**

The Chair welcomed the committee members and attendees to the 6th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

2.

- **RQ8 further discussion**
- **Economic evidence**
- **HE model discussion**

The Chair did a recap of discussions from the last meeting on RQ8 and RQ5. Christiana Dinah asked the committee, if she can share slides in light of the evidence, after reflection of the discussion at the last meeting.

The Chair then introduced Kirsty Luckham (KL) who presented the economic evidence and led the HE model discussion for RQ7 with the committee. The committee had the opportunity to engage and ask questions.

## **3. Macular Oedema treatments NMA (RQ7)**

- **Summary of potential included studies**
- **Discussions of potential included studies**
- **Discussion of interventions, treatment pathways and model design**

The Chair introduced Ahmed Yosef (AY) who reviewed the summary of potential included studies for Macular Oedema treatments NMA (RQ7). AY led a discussion of the potential included studies, interventions, treatment pathways and model design for (RQ7) with the committee.

4.

- **HE model discussion continued**
- **Continued discussion of RQ7**

KL continued the HE model and RQ7 discussion with the committee. The committee had the opportunity to engage and ask questions.

## **5. Rapid glucose lowering (RQ 3)**

- **Evidence review**

AY reviewed the evidence for rapid glucose lowering (RQ3) with the committee. The committee had the opportunity to engage and ask questions.

## **6. Discussion of evidence and recommendation drafting (RQ3)**

The committee discussed the evidence presented and the recommendations were drafted for (RQ3).

**7. Continued discussion and recommendation drafting (RQ3)**

The committee continued the discussion based on the evidence presented and recommendations were drafted for (RQ3).

**8. AOB, summary and next steps**

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.